{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T13:24:39Z","timestamp":1791033879557,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,3,2]],"date-time":"2010-03-02T00:00:00Z","timestamp":1267488000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s11899-010-0045-y","type":"journal-article","created":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T09:25:14Z","timestamp":1267435514000},"page":"70-80","source":"Crossref","is-referenced-by-count":50,"title":["Tyrosine Kinase Inhibitors: The First Decade"],"prefix":"10.1007","volume":"5","author":[{"given":"Meetu","family":"Agrawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravin J.","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Quint\u00e1s-Cardama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,3,2]]},"reference":[{"key":"45_CR1","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Cortes J.: Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009, 113:1619\u20131630.","journal-title":"Blood"},{"key":"45_CR2","first-page":"100","volume":"56","author":"E Buchdunger","year":"1996","unstructured":"Buchdunger E, Zimmermann J, Mett H, et al.: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996, 56:100\u2013104.","journal-title":"Cancer Res"},{"key":"45_CR3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","volume":"2","author":"BJ Druker","year":"1996","unstructured":"Druker BJ, Tamura S, Buchdunger E, et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med 1996, 2:561\u2013566.","journal-title":"Nature Med"},{"key":"45_CR4","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O\u2019Brien","year":"2003","unstructured":"O\u2019Brien SG, Guilhot F, Larson RA, et al.: Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003, 348:994\u20131004.","journal-title":"N Engl J Med"},{"key":"45_CR5","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"BJ Druker","year":"2006","unstructured":"Druker BJ, Guilhot F, O\u2019Brien SG, et al.: Five-year follow up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408\u20132417.","journal-title":"N Engl J Med"},{"key":"45_CR6","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 O\u2019Brien SG, Guilhot F, Goldman JM, et al.: International Randomized Study of Interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 186. The 7-year update of the IRIS trial not only confirmed that imatinib produces significantly higher complete cytogenetic response rates than IFN-\u03b1 and ara-C but also warned about the presence of a sizeable fraction of patients who will discontinue imatinib therapy for safety or efficacy reasons.","DOI":"10.1182\/blood.V112.11.186.186"},{"key":"45_CR7","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","volume":"108","author":"L Roy","year":"2006","unstructured":"Roy L, Guilhot J, Krahnke T, et al.: Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006, 108:1478\u20131484.","journal-title":"Blood"},{"key":"45_CR8","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","volume":"26","author":"H Lavallade de","year":"2008","unstructured":"de Lavallade H, Apperley JF, Khorashad JS, et al.: Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008, 26:3358\u20133363.","journal-title":"J Clin Oncol"},{"key":"45_CR9","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","volume":"108","author":"HM Kantarjian","year":"2006","unstructured":"Kantarjian HM, Talpaz M, O\u2019Brien S, et al.: Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006, 108:1835\u20131840.","journal-title":"Blood"},{"key":"45_CR10","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, et al.: Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006, 108:1809\u20131820.","journal-title":"Blood"},{"key":"45_CR11","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","volume":"112","author":"D Marin","year":"2008","unstructured":"Marin D, Milojkovic D, Olavarria E, et al.: European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008, 112:4437\u20134444.","journal-title":"Blood"},{"key":"45_CR12","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.24418","volume":"115","author":"Y Alvarado","year":"2009","unstructured":"Alvarado Y, Kantarjian H, O\u2019Brien S, et al.: Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 2009, 115:3709\u20133718.","journal-title":"Cancer"},{"key":"45_CR13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","volume":"16","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Kantarjian HM, Cortes JE, et al.: Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 2009, 16:122\u2013131.","journal-title":"Cancer Control"},{"key":"45_CR14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2006.07.010","volume":"249","author":"JV Melo","year":"2007","unstructured":"Melo JV, Chuah C: Resistance to imatinib mesylate in chronic myeloid leukemia. Cancer Lett 2007, 249:121\u2013132.","journal-title":"Cancer Lett"},{"key":"45_CR15","doi-asserted-by":"crossref","unstructured":"Branford S: Chronic myeloid leukemia: molecular monitoring in clinical practice. Hematology Am Soc Hematol Educ Program 2007, 376\u2013383.","DOI":"10.1182\/asheducation-2007.1.376"},{"key":"45_CR16","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1182\/blood-2005-03-1036","volume":"106","author":"SG Willis","year":"2005","unstructured":"Willis SG, Lange T, Demehri S, et al.: High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005; 106:2128\u20132137.","journal-title":"Blood"},{"key":"45_CR17","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","volume":"117","author":"NP Shah","year":"2007","unstructured":"Shah NP, Skaggs BJ, Branford S, et al.: Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007, 117:2562\u20132569.","journal-title":"J Clin Invest"},{"key":"45_CR18","doi-asserted-by":"crossref","unstructured":"Quint\u00e1s-Cardama A, Gibbons DL, Kantarjian HM, et al.: Mutational analysis of chronic phase chronic myeloid leukemia (CML-CP) clones reveals heightened BCR-ABL1 genetic instability in patients failing sequential imatinib and dasatinib therapy [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 2114.","DOI":"10.1182\/blood.V112.11.2114.2114"},{"key":"45_CR19","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","volume":"83","author":"L Wang","year":"2008","unstructured":"Wang L, Giannoudis A, Lane S, et al.: Expression of the uptake drug transported hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008, 83:258\u2013264.","journal-title":"Clin Pharmacol Ther"},{"key":"45_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428190500407996","volume":"47","author":"J Goldman","year":"2006","unstructured":"Goldman J, Gordon M.: Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: Does it really matter? Leuk Lymphoma 2006, 47:1\u20137.","journal-title":"Leuk Lymphoma"},{"key":"45_CR21","doi-asserted-by":"crossref","unstructured":"Aoki E, Kantarjian HM, O\u2019Brien S, et al.: High-dose imatinib mesylate treatment in patients with untreated early chronic phase chronic myeloid leukemia: 2.5-year follow-up [abstract]. J Clin Oncol 2006, 24(18S):Abstract 6535.","DOI":"10.1200\/jco.2006.24.18_suppl.6535"},{"key":"45_CR22","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","volume":"112","author":"TP Hughes","year":"2008","unstructured":"Hughes TP, Branford S, White DL, et al.: Impact of early dose intensity on cytogenetic and molecular responses in chronic phase CML patients receiving 600\u00a0mg\/day of imatinib as initial therapy. Blood 2008, 112:3965\u20133973.","journal-title":"Blood"},{"key":"45_CR23","doi-asserted-by":"crossref","unstructured":"Cortes J, Baccarani M, Guilhot F, et al.: A phase III, randomized, open label study of 400\u00a0mg versus 800\u00a0mg of imatinib mesylate in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) study [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 335.","DOI":"10.1182\/blood.V112.11.335.335"},{"key":"45_CR24","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","volume":"113","author":"E Jabbour","year":"2009","unstructured":"Jabbour E, Kantarjian HM, Jones D, et al.: Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood 2009, 113:2154\u20132160.","journal-title":"Blood"},{"key":"45_CR25","doi-asserted-by":"crossref","unstructured":"Guilhot F, Mahon F-X, Guilhot J, et al.: Randomized comparison of imatinib versus imatinib combination therapies in newly diagnosed chronic myeloid leukaemia (CML) patients in chronic phase (CP): first results of the phase III (SPIRIT) trial from the French CML group (FI LMC) [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 183.","DOI":"10.1182\/blood.V112.11.183.183"},{"key":"45_CR26","doi-asserted-by":"crossref","unstructured":"Hehlmann R, Saussele S, Lauseker M, et al.: Randomized comparison of imatinib 400\u00a0mg vs. imatinib + IFN vs. imatinib + araC vs. imatinib after IFN vs. imatinib 800\u00a0mg: optimized treatment and survival. Designed first interim analysis of the German CML Study IV [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 184.","DOI":"10.1182\/blood.V112.11.184.184"},{"key":"45_CR27","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix U, Hantschel O, Durnberger G, et al.: Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and non kinase targets. Blood 2007, 110:4055\u20134063.","journal-title":"Blood"},{"key":"45_CR28","doi-asserted-by":"crossref","unstructured":"Baccarani M, Rosti G, Saglio G, et al.: Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 450.","DOI":"10.1182\/blood.V112.11.450.450"},{"key":"45_CR29","doi-asserted-by":"crossref","unstructured":"\u2022 Mauro MJ, Baccarani M, Cervantes F, et al.: Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) [abstract]. J Clin Oncol 2008, 26(suppl):Abstract 7009. The START-C trial showed the efficacy of dasatinib in patients with CP CML who were resistant or intolerant to imatinib. Responses were seen across all mutations except T315I.","DOI":"10.1200\/jco.2008.26.15_suppl.7009"},{"key":"45_CR30","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1200\/JCO.2007.14.3339","volume":"27","author":"JF Apperley","year":"2009","unstructured":"Apperley JF, Cortes JE, Kim DW, et al.: Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. J Clin Oncol 2009, 27:3472\u20133479.","journal-title":"J Clin Oncol"},{"key":"45_CR31","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2008.221","volume":"22","author":"J Cortes","year":"2008","unstructured":"Cortes J, Kim DW, Raffoux E, et al.: Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 2008, 22:2176\u20132183.","journal-title":"Leukemia"},{"key":"45_CR32","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","volume":"115","author":"H Kantarjian","year":"2009","unstructured":"Kantarjian H, Pasquini R, L\u00e9vy V, et al.: Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistance to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer 2009, 115:4136\u20134147.","journal-title":"Cancer"},{"key":"45_CR33","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2008.11.001","volume":"14","author":"NP Shah","year":"2008","unstructured":"Shah NP, Kasap C, Weier C, et al.: Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008, 14:485\u2013493.","journal-title":"Cancer Cell"},{"key":"45_CR34","doi-asserted-by":"crossref","unstructured":"Stone RM, Kim DW, Kantarjian HM, et al.: Dasatinib dose-optimization study in chronic phase chronic myeloid leukemia (CML-CP): Three-year follow-up with dasatinib 100\u00a0mg once daily and landmark analysis of cytogenetic response and progression-free survival [abstract]. J Clin Oncol 2009, 27(suppl):Abstract 7007.","DOI":"10.1200\/jco.2009.27.15_suppl.7007"},{"key":"45_CR35","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1002\/cncr.24325","volume":"115","author":"A Quint\u00e1s-Cardama","year":"2009","unstructured":"Quint\u00e1s-Cardama A, Cortes J, O\u2019Brien S, et al.: Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer 2009, 115:2912\u20132921.","journal-title":"Cancer"},{"key":"45_CR36","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Cortes J, O\u2019Brien S, Borthakur G, et al.: Efficacy of dasatinib in patients with previously untreated chronic myelogenous leukemia in early chronic phase (CML-CP) [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 182. This phase 2 trial demonstrated that dasatinib therapy is very efficacious and safe when administered as frontline therapy to patients with previously untreated CP CML.","DOI":"10.1182\/blood.V112.11.182.182"},{"key":"45_CR37","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s11523-006-0032-3","volume":"1","author":"E Jabbour","year":"2006","unstructured":"Jabbour E, Cortes J, Giles F, et al.: The clinical challenge of imatinib resistance in chronic myeloid leukemia: emerging strategies with new targeted agents. Targ Oncol 2006, 1:186\u2013196.","journal-title":"Targ Oncol"},{"key":"45_CR38","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Kantarjian H, Giles F, Bhalla K, et al.: Nilotinib in chronic myeloid leukemia patients in chronic phase with imatinib resistance or intolerance: longer follow-up of a phase II study [abstract]. J Clin Oncol 2009, 27(suppl):Abstract 7029. This phase 2 study showed the high efficacy and safety of nilotinib in patients with CP CML who were intolerant or resistant to imatinib.","DOI":"10.1200\/jco.2009.27.15_suppl.7029"},{"key":"45_CR39","doi-asserted-by":"crossref","unstructured":"Le Coutre PD, Giles F, Hochhaus A, et al.: Nilotinib in chronic myeloid leukemia patients in accelerated phase with imatinib resistance or intolerance: longer follow-up results of a phase II study [abstract]. J Clin Oncol 2009, 27(suppl):Abstract 7057.","DOI":"10.1200\/jco.2009.27.15_suppl.7057"},{"key":"45_CR40","doi-asserted-by":"crossref","unstructured":"\u2022 Giles FJ, Larson RA, Kantarjian HM, et al.: Nilotinib in patients with Philadelphia chromosome positive chronic myelogenous leukemia in blast crisis (CML-BC) who are resistant or intolerant to imatinib [abstract]. J Clin Oncol 2008, 26(suppl):Abstract 7017. This phase 2 study showed that nilotinib can be effective in patients presenting in blast phase after the failure of imatinib treatment.","DOI":"10.1200\/jco.2008.26.15_suppl.7017"},{"key":"45_CR41","doi-asserted-by":"crossref","unstructured":"Giles F, le Coutre PD, Bhalla KN, et al.: Efficacy and tolerability of nilotinib in chronic myeloid leukemia patients in chronic phase who failed prior imatinib and dasatinib therapy; updated results of a phase 2 study [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 3234.","DOI":"10.1182\/blood.V112.11.3234.3234"},{"key":"45_CR42","doi-asserted-by":"crossref","unstructured":"Jabbour E, Kantarjian H, Baccarani M, et al.: Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myeloid leukemia in chronic phase or accelerated phase [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 3215.","DOI":"10.1200\/jco.2008.26.15_suppl.7063"},{"key":"45_CR43","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Cortes J, O\u2019Brien S, Jones D, et al.: Efficacy of nilotinib (formerly AMN107) in patients with newly diagnosed, previously untreated Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase (CML-CP) [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 446. This phase 2 study showed that nilotinib is very effective as frontline therapy for patients with newly diagnosed CP CML.","DOI":"10.1200\/jco.2008.26.15_suppl.7016"},{"key":"45_CR44","doi-asserted-by":"crossref","unstructured":"Martinelli G, Castagnetti F, Poerio A, et al.: Molecular responses with nilotinib 800\u00a0mg daily as first-line treatment of chronic myeloid leukemia in chronic phase: results of a phase II trial of the GIMEMA CML WP [abstract]. J Clin Oncol 2009, 27(suppl):Abstract 7074.","DOI":"10.1200\/jco.2009.27.15_suppl.7074"},{"key":"45_CR45","doi-asserted-by":"crossref","unstructured":"Gambacorti-Passerini C, Kantarjian H, Bruemmendorf T, et al.: Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated among patients with AP and BP CML and Ph + ALL [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 146.","DOI":"10.1182\/blood.V110.11.473.473"},{"key":"45_CR46","doi-asserted-by":"crossref","unstructured":"Cortes J, Kantarjian M, Baccarani M, et al.: A phase 1\/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive chronic myelogenous leukemia or acute lymphoblastic leukemia relapsed, refractory or intolerant of imatinib [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 54.","DOI":"10.1182\/blood.V108.11.168.168"},{"key":"45_CR47","doi-asserted-by":"crossref","unstructured":"Cortes J, Kantarjian HM, Kim DW, et al.: Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph + chronic myelogenous leukemia with resistance or intolerance to imatinib [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 1098.","DOI":"10.1182\/blood.V112.11.1098.1098"},{"key":"45_CR48","doi-asserted-by":"crossref","unstructured":"Gambacorti-Passerini C, Pogliani EM, Baccarani M, et al.: Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated in patients with AP and BP CML and Ph + ALL [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 1101.","DOI":"10.1182\/blood.V112.11.1101.1101"},{"key":"45_CR49","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/blood-2006-03-013250","volume":"109","author":"A Yokota","year":"2007","unstructured":"Yokota A, Kimura S, Masuda S, et al.: INNO-406, a novel BCR-ABL\/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph + leukemic cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 2007, 109:306\u2013314.","journal-title":"Blood"},{"key":"45_CR50","doi-asserted-by":"crossref","unstructured":"Pinilla-Ibarz J, Kantarjian HM, Cortes J, et al.: A phase I study of INNO-406 in patients with advanced Philadelphia chromosome-positive (Ph+) leukemias who are resistant or intolerant to imatinib and may have also failed second-generation tyrosine kinase inhibitors [abstract]. J Clin Oncol 2008, 26(suppl):Abstract 7018.","DOI":"10.1200\/jco.2008.26.15_suppl.7018"},{"key":"45_CR51","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd2324","volume":"6","author":"A Quint\u00e1s-Cardama","year":"2007","unstructured":"Quint\u00e1s-Cardama A, Kantarjian H, Cortes J, et al.: Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007, 6:834\u2013848.","journal-title":"Nat Rev Drug Discov"},{"key":"45_CR52","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm1003","volume":"10","author":"EA Harrington","year":"2004","unstructured":"Harrington EA, Bebbington D, Moore J, et al.: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004, 10:262\u2013267.","journal-title":"Nat Med"},{"key":"45_CR53","doi-asserted-by":"crossref","unstructured":"Giles F, Cortes J, Bergstrom DA, et al.: MK-0457, a novel aurora kinase and BCR-ABL inhibitor, is active against BCR-ABL T3151 mutant chronic myelogenous leukemia [abstract]. Blood (ASH Annual Meeting Abstracts) 2006, 108:Abstract 52.","DOI":"10.1182\/blood.V108.11.163.163"},{"key":"45_CR54","doi-asserted-by":"crossref","unstructured":"Cortes J, Paquette R, Talpaz M, et al.: Preliminary clinical activity in a phase I trial of the bcr-abl\/IGF-1R\/aurora kinase inhibitor XL228 in patients with Ph + leukemias with either failure to multiple TKI therapies or with T315I mutation [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 3232.","DOI":"10.1182\/blood.V112.11.3232.3232"},{"key":"45_CR55","doi-asserted-by":"crossref","unstructured":"Paquette RL, Shah NP, Sawyers CL, et al.: PHA-739358, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 1030.","DOI":"10.1182\/blood.V110.11.1030.1030"},{"key":"45_CR56","doi-asserted-by":"crossref","unstructured":"O\u2019Hare T, Eide CA, Adrian LT, et al.: Complete suppression of in vitro resistance by AP24534, a Pan-Bcr-Abl inhibitor [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 726.","DOI":"10.1182\/blood.V112.11.726.726"},{"key":"45_CR57","doi-asserted-by":"crossref","unstructured":"Rivera VM, Xu Q, Wang F, et al.: Potent antitumor activity of AP24534, an orally active inhibitor of Bcr-Abl variants including T315I, in in vitro and in vivo models of chronic myeloid leukemia (CML) [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 1032.","DOI":"10.1182\/blood.V110.11.1032.1032"},{"key":"45_CR58","unstructured":"Squires MS, Reule M, Curry J, et al.: AT9283, a potent inhibitor of BCR-ABL T315I is active in CML models [abstract 2820]. Presented at the Annual Meeting of the American Association of Cancer Research. San Diego, CA, April 12\u201316, 2008."},{"key":"45_CR59","doi-asserted-by":"crossref","unstructured":"Van Etten RA, Chan WW, Zaleskas VM, et al.: DCC-2036: a novel switch pocket inhibitor of ABL tyrosine kinase with therapeutic efficacy against BCR-ABL T315I in vitro and in a CML mouse model [abstract]. Blood (ASH Annual Meeting Abstracts) 2007, 110:Abstract 142.","DOI":"10.1182\/blood.V110.11.463.463"},{"key":"45_CR60","doi-asserted-by":"crossref","unstructured":"Van Etten RA, Chan WW, Zaleskas VM, et al.: Switch pocket inhibitors of the ABL tyrosine kinase: distinct kinome inhibition profiles and in vivo efficacy in mouse models of CML and B-lymphoblastic leukemia induced by BCR-ABL T315I [abstract]. Blood (ASH Annual Meeting Abstracts) 2008, 112:Abstract 576.","DOI":"10.1182\/blood.V112.11.576.576"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-010-0045-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-010-0045-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-010-0045-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T05:20:24Z","timestamp":1635052824000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-010-0045-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,2]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["45"],"URL":"https:\/\/doi.org\/10.1007\/s11899-010-0045-y","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,2]]}}}